0001213900-23-002882.txt : 20230117 0001213900-23-002882.hdr.sgml : 20230117 20230113191535 ACCESSION NUMBER: 0001213900-23-002882 CONFORMED SUBMISSION TYPE: 424B8 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230117 DATE AS OF CHANGE: 20230113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JPMORGAN CHASE & CO CENTRAL INDEX KEY: 0000019617 STANDARD INDUSTRIAL CLASSIFICATION: NATIONAL COMMERCIAL BANKS [6021] IRS NUMBER: 132624428 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-236659 FILM NUMBER: 23529934 BUSINESS ADDRESS: STREET 1: 383 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2122706000 MAIL ADDRESS: STREET 1: 383 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: J P MORGAN CHASE & CO DATE OF NAME CHANGE: 20010102 FORMER COMPANY: FORMER CONFORMED NAME: CHASE MANHATTAN CORP /DE/ DATE OF NAME CHANGE: 19960402 FORMER COMPANY: FORMER CONFORMED NAME: CHEMICAL BANKING CORP DATE OF NAME CHANGE: 19920703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JPMorgan Chase Financial Co. LLC CENTRAL INDEX KEY: 0001665650 STANDARD INDUSTRIAL CLASSIFICATION: NATIONAL COMMERCIAL BANKS [6021] IRS NUMBER: 475462128 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-236659-01 FILM NUMBER: 23529935 BUSINESS ADDRESS: STREET 1: 383 MADISON AVENUE STREET 2: FLOOR 21 CITY: NEW YORK STATE: NY ZIP: 10179 BUSINESS PHONE: (212) 270-6000 MAIL ADDRESS: STREET 1: 383 MADISON AVENUE STREET 2: FLOOR 21 CITY: NEW YORK STATE: NY ZIP: 10179 424B8 1 s148118_424b8.htm FORM 424B8
January 13, 2023 Registration Statement Nos. 333-236659 and 333-236659-01; Rule 424(b)(8)

 

JPMorgan Chase Financial Company LLC
Structured Investments

Auto Callable Contingent Interest Notes Linked to the Least Performing of the Common Stock of Tesla, Inc., the Common Stock of Amazon.com, Inc. and the Class A Common Stock of Meta Platforms, Inc. due January 2, 2026

Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.

The section entitled “Comparable Yield and Projected Payment Schedule” in the pricing supplement dated December 29, 2022, related to the notes referred to above (the “pricing supplement”), is amended, restated and superseded in its entirety by the following:

Comparable Yield and Projected Payment Schedule

We have determined that the “comparable yield” is an annual rate of 4.89% compounded quarterly. Based on our determination of the comparable yield, the “projected payment schedule” per $1,000 principal amount note consists of the following payments:

Payment Dates Projected Payment Amounts
April 3, 2023 $25.62
July 5, 2023 $19.26
October 4, 2023 $15.83
January 4, 2024 $13.59
April 4, 2024 $12.12
July 5, 2024 $10.74
October 3, 2024 $9.80
January 3, 2025 $8.91
April 3, 2025 $8.05
July 3, 2025 $7.24
October 2, 2025 $6.63
January 2, 2026 $1,006.04

In addition, assuming a quarterly accrual period, the following table states the amount of OID that will accrue with respect to the notes during each calendar period, based upon our determination of the comparable yield and the projected payment schedule. The table does not account for adjustments to reflect the difference between the actual and projected amount of any payment you receive during each year.

Calendar Period Accrued OID During Calendar Period
(Per $1,000 Principal Amount Note)
Total Accrued OID from Original Issue Date
(Per $1,000 Principal Amount Note) as of
End of Calendar Period
Original Issue Date through December 31, 2023 $47.70 $47.70
January 1, 2024 through December 31, 2024 $47.60 $95.30
January 1, 2025 through December 31, 2025 $48.19 $143.49
January 1, 2026 through January 2, 2026 $0.33 $143.83

The comparable yield and projected payment schedule are determined solely to calculate the amount on which you will be taxed with respect to the notes in each year and are neither a prediction nor a guarantee of what the actual yield or timing of the payment or payments will be. The amounts you actually receive each year, including at maturity or earlier sale or exchange of your notes, will affect your income for that year, as described under “Treatment as Contingent Payment Debt Instruments” in the pricing supplement.

CUSIP: 48133PB51

Investing in the notes involves a number of risks. See “Risk Factors” beginning on page S-2 of the accompanying prospectus supplement, “Risk Factors” beginning on page PS-10 of the accompanying product supplement and “Selected Risk Considerations” beginning on page PS-5 of the pricing supplement.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this amendment, the pricing supplement or the accompanying product supplement, underlying supplement, prospectus supplement and prospectus. Any representation to the contrary is a criminal offense.

The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank

You should read this amendment together with the pricing supplement and the related product supplement, underlying supplement, prospectus supplement and prospectus, each of which can be accessed via the hyperlinks below. Please also see “Additional Terms Specific to the Notes” in the pricing supplement.

Pricing supplement dated December 29, 2022:

http://www.sec.gov/Archives/edgar/data/1665650/000121390023000442/s147720_424b2.htm

Product supplement no. 3-II dated November 4, 2020:
http://www.sec.gov/Archives/edgar/data/19617/000095010320021466/crt_dp139321-424b2.pdf

Prospectus supplement and prospectus, each dated April 8, 2020:
http://www.sec.gov/Archives/edgar/data/19617/000095010320007214/crt_dp124361-424b2.pdf

 

 

Amendment no. 1 to pricing supplement dated December 29, 2022 to product supplement no. 3-II dated November 4, 2020

and the prospectus and prospectus supplement, each dated April 8, 2020